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Mumps virus is a highly neurotropic virus with evidence of central nervous system invasion (CNS) in approximately half of all cases of
infection. In countries where live attenuated mumps virus vaccines were introduced, the number of mumps cases declined dramatically; however,
recently, the safety of some vaccine strains has been questioned. For example, one of the most widely used vaccines, the Urabe AM9 strain, was
causally associated with meningitis, leading to the withdrawal of this product from the market in several countries. This highlights the need for a
better understanding of the attenuation process and the identification of markers of attenuation. To this end, we further attenuated the Urabe AM9
strain by serial passage in cell culture and compared the complete nucleotide sequences of the parental and passaged viruses. Interestingly, despite
a dramatic decrease in virus virulence (as assayed in rats), the only genomic changes were in the form of changes in the level of genetic
heterogeneity at specific genome sites, i.e., either selection of one nucleotide variant at positions where the starting material exhibited nucleotide
heterogeneity or the evolution of an additional nucleotide to create a heterogenic site. This finding suggests that changes in the level of genetic
heterogeneity at specific genome sites can have profound neurovirulence phenotypic consequences and, therefore, caution should be exercised
when evaluating genetic markers of virulence or attenuation based only on a consensus sequence.
Published by Elsevier Inc.Keywords: Mumps virus; Vaccine; Urabe AM9; Central nervous system; Neurovirulence; Neuroattenuation; Quasispecies; Rat model; Genetic heterogeneityIntroduction
Mumps virus is a member of the genus Rubulavirus within
the family Paramyxoviridae (order Mononegavirales). Its
single-stranded negative sense RNA genome consists of
15,384 nucleotides containing seven tandemly linked transcrip-
tion units that encode seven open reading frames: the gene order
is NP (nucleoprotein), V/P (phosphoprotein), M (matrix), F
(fusion), SH (small hydrophobic), HN (hemagglutinin-neur-
aminidase) and L (large). Each open reading frame encodes the
indicated protein, with the exception of the P open reading
frame, which encodes three proteins, P, V and I via an RNA
editing process (Paterson and Lamb, 1990; Elliott et al., 1990).⁎ Corresponding author. Fax: +1 301 480 5679.
E-mail address: rubins@cber.fda.gov (S.A. Rubin).
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doi:10.1016/j.virol.2006.01.035Mumps is an acute, communicable disease transmitted via
the respiratory route. Mumps virus infection often results in
viremia with dissemination of virus to a number of organ
systems, including the central nervous system (CNS). The
predilection of the virus for the CNS was suggested in a study
by Bang and Bang (1943) demonstrating cerebrospinal fluid
pleocytosis in 65% of mumps cases. Later, epidemiological
studies would reveal mumps virus as a leading cause of virus-
induced aseptic meningitis and encephalitis in the United States
and Europe (Carbone and Wolinsky, 2001).
With the advent of live attenuated mumps virus vaccines, the
incidence of mumps dropped dramatically in countries where
universal vaccination was implemented, demonstrating an
overall high efficiency of these vaccines. However, some
vaccines, including the Urabe AM9, Leningrad–Zagreb and
Sofia-6, have been found to cause excessive neurological
adverse reactions, including aseptic meningitis (Odisseev and
Fig. 1. Amount of Urabe P-AM9 recovered from Vero and CEF cells after
repeated passaging. Urabe P-AM9 was passaged six times in Vero and CEF cell
lines. Each infection was done at an m.o.i. of 0.05 or lower (see Materials and
methods for further information). Virus was harvested when more than 90% of
cells were lysed, or, in the absence of detectable cell lysis, at day 7 p.i. Virus
titers after each passage were determined at least twice independently. Error bars
represent standard error of the mean.
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2002; Azzopardi, 1988; Furesz, 2002). Such problems have
resulted in vaccine withdrawal, removal of mumps vaccine from
national immunization programs and public resistance to
vaccination. One of the best studied of these strains is the
Urabe AM9 vaccine. That rates of meningitis after vaccination
with the Urabe AM9 strain differed not only by manufacturer
but also by formulation (reviewed in (Plotkin and Wharton,
1999)) and that Urabe AM9 exhibits substantial genetic
variability (Brown and Wright, 1998; Brown et al., 1996;
Afzal et al., 1998; Mori et al., 1997; Amexis et al., 2001),
strongly suggests the role of virus strain variants in disease-
inducing potential. Previous studies of the causal association
between Urabe AM9 sequence differences and virulence are
difficult to interpret due to the fact that genetic analyses were
limited to a subset of the virus genes (mostly the HN gene) and
relied on passive reporting of adverse events (Brown et al.,
1996; Amexis et al., 2001; Afzal et al., 1998). To overcome
these limitations, we developed two neuroattenuated variants of
the Urabe AM9 vaccine strain (through serial passages in cell
culture) and fully sequenced all three viruses. The neuroviru-
lence of these viruses was assessed in rats, a system in which the
relative human neurovirulence potential of mumps virus strains
can be quantitatively assessed (Rubin et al., 2000; Rubin et al.,
2005). Genomic changes associated with neuroattenuation were
then identified. Interestingly, the only genomic changes
associated with attenuation were in form of changes in the
level of genetic heterogeneity at specific genome sites, i.e.,
disappearance and evolution of nucleotide heterogeneity at
various positions. Expectedly, many of the changes associated
with attenuation were specific to the cell line used, however, in at
least one instance, an identical mutation independently evolved
in both passaged viruses. The possible relevance of the identified
changes with respect to neurovirulence phenotype is discussed.
Results
Attenuation of Urabe P-AM9 by passage in Vero and CEF cells
CEF and monkey kidney cells have proved to be suitable for
attenuation of wild type mumps virus isolates (Plotkin and
Wharton, 1999). Therefore, Urabe P-AM9 virus was passaged
six times on CEF and Vero cells to create two virus stocks,
Urabe-P6-CEF and Urabe-P6-Vero. The in vitro growth curves
obtained during passaging showed that in both cell lines viral
titers dropped during the first three passages but then gradually
increased over the subsequent three passages, suggesting that
adaptation to the respective cell lines occurred (Fig. 1).
Notably, however, infectious virus titers did not recover to
initial levels. To analyze changes in the neurovirulence
potential of Urabe P-AM9 passaged in Vero and CEF cells,
parental Urabe P-AM9, Urabe-P6-Vero and Urabe-P6-CEF
were tested in the newborn rat neurovirulence model. In
comparison to the parental Urabe P-AM9, the neurovirulence
scores for Urabe-P6-Vero and Urabe-P6-CEF were reduced by
81% and 86%, respectively (Fig. 2). These differences were
statistically significant (P =b 0.001, Mann–Whitney Rank SumTest). Thus, using this quantitative disease model, we could
demonstrate that passaging of Urabe P-AM9 in both cell lines
led to a significant reduction in neurovirulence. Of note, the
mean neurovirulence score of Urabe P-AM9 (10.7) is less than
typical neurovirulence scores of wild type viruses (usually
ranging from 15 to 25), but substantially greater than neuro-
virulence scores typical of attenuated vaccine strains (usually
ranging from 0 to 5) (Rubin et al., 1998, 2000, 2003, 2005).
Reduction in neurovirulence phenotype is associated with only
a slight decreased ability to replicate in the brain
To investigate if the neurovirulent and neuroattenuated
viruses differed in their ability to replicate in the brain, we
compared Urabe P-AM9 and Urabe P6-CEF virus growth in rat
brain over a 10-day period. As shown in Fig. 3, both viruses
exhibited similar growth kinetics in rat brain: Virus titers (1)
reached maximum values around day 3 p.i., (2) steadily declined
until day 6 p.i., and (3) after day 6 p.i., both viruses appeared to
stabilize in titer. However, while a two way analysis of variance
(ANOVA) did not reveal a statistically significant difference
among the two virus strains over the entire time course
(P = 0.055), post hoc testing (Mann–Whitney rank sum test)
revealed statistically significant differences between the two
viruses at day 2 p.i. (P = 0.023), and day 3 p.i. (P = 0.023), where
viral titers were approximately one log lower in brains of Urabe
P6-CEF infected rats compared to Urabe P-AM9 infected rats.
Neuroattenuation is associated with changes in the level of
genetic heterogeneity at specific genome sites
To associate the observed changes in neurovirulence between
Urabe P-AM9, Urabe P6-Vero, and Urabe P6-CEF with changes
in the viral genomes, the complete direct sequences of the three
virus genomes were determined and are summarized in Table 1.
Fig. 3. Virus growth in rat brains inoculated with Urabe P-AM9 and Urabe P6-
CEF. For Urabe P6-CEF, five rats were analyzed per time point. In case of Urabe
P-AM9, nine rats each were analyzed for days 2, 3, 4 and 6 p.i.; five rats for day
5 p.i. and four rats for day 10 p.i. Error bars represent standard errors of the mean.
Fig. 2. Severity of hydrocephalus in rats inoculated with Urabe P-AM9, Urabe
P6-Vero and Urabe P6-CEF. Newborn rats were inoculated i.c. with the
respective viruses and euthanized 30 days later. Brains were processed for
histology and the hydrocephalus score was calculated as described in materials
and methods. The number of animals tested per different viruses is indicated.
Mock: inoculation of rats with noninfectious cell culture supernatant. Error bars
represent standard error of the mean.
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parent and the two passaged viruses were in the form of changes
in genetic heterogeneity, i.e., either selection of one nucleotide
variant at positions where the starting material exhibited genetic
heterogeneity or the evolution of an additional nucleotide to
create a heterogenic site, i.e., without the loss of the original
nucleotide sequence. Subcloning and sequencing of selected
PCR fragments confirmed heterogeneous sites identified in the
electropherograms (Table 1).
Fifteen heterogeneous sites were identified in parental Urabe
P-AM9, all of which became monotypic in the neuroattenuated
Urabe P6-CEF strain (i.e., only one of the two nucleotides at
heterogeneous sites in the parental virus were present in the
passaged virus). At roughly half of these sites, selection took
place in favor of the nucleotide that predominated in Urabe P-
AM9, while at four sites selection for the less frequent parental
nucleotide occurred. In the remaining sites where parental hete-
rogeneity was lost, the ratio of nucleotides was found at approxi-
mately 1:1 in the parent virus. In addition to loss of heterogeneity,
at five sites there was an apparent “gain” in heterogeneity, i.e.,
sites that were formally monotypic in the parental virus became
heterogeneous upon passage in CEF cells. At two of these sites,
the nucleotide present in the parental virus predominated at the
new heterogeneous site in the passaged virus whereas at two
other sites the newly evolved nucleotide predominated. Amino
acid changes were predicted for three out of the five sites of new
heterogeneity (one each in the NP, F and HN proteins).
In comparing the parental Urabe P-AM9 to the neuroatte-
nuated Urabe P6-Vero, seven of the 15 heterogeneous sites in
the parental virus became monotypic. Selection at all seven
positions took place in favor of the nucleotide that predomi-
nated in the parental virus. Of the eight heterogeneous sites that
were preserved in the passage process, nucleotide predominance
was maintained at three sites and was reversed at four sites. Forthe remaining site, the ratio of the two nucleotides in the parental
virus was approximately 1:1. In addition to loss of heterogeneity,
at eight sites there was an apparent gain in heterogeneity upon
passage in Vero cells. At all eight sites, the parental nucleotide
either predominated or existed at an equivalent proportion to the
newly evolved nucleotide. The changes observed at seven out of
these eight positions were coding changes (two each in the F and
HN genes and three in the L gene. The remaining position was
identified in the nontranslated intergenic region between the NP
and V/P genes.
Sequencing of the genome ends also revealed sequence
heterogeneity. In the case of the 3′ end, up to seven different
variants were detected among the three viruses (Urabe AM9,
Urabe-P6-Vero and Urabe-P6-CEF) as shown in Fig. 4, with
genotype “a” predominating in all cases when the RACE system
was used. Interestingly, when the RNA self-ligation method was
used, unique genotypes (“c” and “d”) were additionally
observed. Of note, upon occasion long stretches of A residues
were identified upstream the 3′ end of genotype “d” sequences.
Whether or not this is an artifact of the method is not clear,
though inconsistent results using RNA self-ligation as compared
to 3′RACE have been reported previously (Pleschka et al., 2001;
Rosario et al., 2005). In the case of the 5′ end, the sequences of
all three viruses were identical to the published sequence of the
vaccine, with the exception of a truncated sequence seen in one
out of eight clones of the Urabe-P6-CEF virus (Fig. 4).
Notably, outside of differences in heterogeneous sites, the
nucleotide sequence of Urabe P-AM9 was identical to that of
the published sequence of Urabe AM9 SB, the original vaccine
strain from which Urabe P-AM9 was derived for the present
studies (Amexis et al., 2001; Afzal et al., 1998; Mori et al.,
1997; Brown et al., 1996).
Discussion
Wild type mumps viruses are highly neurotropic, with
evidence of CNS infection in greater than half of all cases (Bang
Table 1
Comparison of the nucleotide sequences of Urabe P-AM9, Urabe P6-CEF and Urabe P6-Vero
Nucleotide Gene (aa position) Urabe P-AM9a Urabe P6-CEFa Urabe P6-Vero a
46 3′ Leader A/G A A/G
(A ≥ G; 6/6) (A ≥ G; 8/3)
195 NP (17) T Leu T/A Leu/His T Leu
(T ≤ A; 9/5)
1880 Intergenic region C C C/A
(C N A; 6/2)
2842 P (289) T/C Leu/Pro T Leu T Leu
(T N C; 5/1)
2843 P (289) T/C Leu T Leu T Leu
(T N C; 5/1)
4903 F (120) C/G Gln/Glu C Gln C/G Gln/Glu
(C ≥ G; 2/3) (C N G; 5/3)
5414 F (290) A/T Tyr/Phe A Tyr A Tyr
(A NT; 3/2)
5653 F (370) A Thr A/G Thr/Ala A/G Thr/Ala
(A b G; 3/4) (A ≤ G; 7/5)
5723 F (393) C Pro C Pro C/T Pro/Leu
(C N T; 10/2)
7365 HN (251) A Asp A Asp A/G Asp/Gly
(A N G; 9/1)
7407 HN (265) C/A Thr/Asn C Thr C Thr
(C N A; 7/2)
7498 HN (295) T/C Thr T Thr T Thr
(T N C; 8/2)
7616 HN (335) A/G Lys/Glu A Lys A/G Lys/Glu
(A = G; 7/7) (A N G; 8/2)
8005 HN (464) C/A Asn/Lys A Lys C/A Asn/Lys
(C ≥ A; 12/7) (C b A; 4/7)
8015 HN (468) G/A Glu/Lys G Glu G/A Glu/Lys
(G N A; 17/2) (G N A; 10/1)
8088 HN (492) A Gln A/G Gln/Arg A Gln
(A b G; 6/3)
8174 HN (521) G Ala G Ala G/A Ala/Thr
(G N A; 9/2)
9918 L (494) G Arg G Arg G/A Arg/Lys
(G = A; 5/3)
9972 L (512) C/T Ser/Phe T Phe C/T Ser/Phe
(C N T; 10/1) (C b T; 2/6)
10529 L (698) C/T Leu T Leu C/T Leu
(C N T; 4/2) (C b T; 1/5)
11107 L (890) G/A Glu G Glu G Glu
(G N A; 3/3)
11521 L (1028) G Met G Met G/A Met/Ile
(G N A; 5/4)
11665 L (1076) C Gly T/C Gly C Gly
(T ≥ C; 5/1)
11692 L (1085) G/T Leu/Phe T Phe G/T Leu/Phe
(G N T; 5/1) (G b T; 1/8)
12291 L (1285) A/G Gln/Arg A Gln A Gln
(A N G; 3/1)
12690 L (1418) A Glu A Glu A/G Glu/Gly
(A N G; 9/1)
12781 L (1448) C His T/C His C His
(T N C; 5/1)
a Parentheses indicate the estimated frequency of the two nucleotides at the respective position based on a qualitative evaluation of electropherograms. The numbers
shown after the semicolon correspond to the numbers of subcloned and sequenced PCR fragments that possess the respective nucleotides.
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neurological complication of mumps is aseptic meningitis,
though more severe consequences including permanent
deafness and fatal encephalitis can occur (Koskiniemi et al.,
1983; Modlin et al., 1975; Timmons and Johnson, 1970;Ogata et al., 1992; Nussinovitch et al., 1992; Venketasubra-
manian, 1997; Cohen et al., 1992; Ichiba et al., 1988; Bitnun
et al., 1986).
Attenuation of such pathogenic characteristics is a prereq-
uisite for use of a live mumps virus vaccine. However, the
Fig. 4. Sequence heterogeneity observed in Urabe AM9 3′ and 5′ termini.
Summary of the different sequences of 3′ and 5′ termini identified in Urabe P-
AM9, Urabe P6-Vero and Urabe P6-CEF, as determined by 3′ RACE, 5′ RACE
or RNA self-ligation. A total of 15 clones of the 3′ region and 14 clones of the 5′
region were sequenced using the RACE kits. In addition, 15 subcloned RT-PCR
fragments that were obtained using the RNA self-ligation method, were
sequenced. The sequences designated “a” are the predominant sequences
observed. Sequences designated bc" and bd" were only observed using the RNA
self-ligation method.
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new strains of mumps vaccine continue to be licensed for
clinical use, identifying the molecular basis of mumps virus
neurovirulence will be of growing value for support of vaccine
safety.
The classical approach to attenuation of wild type viruses to
produce live virus vaccines is serial passage of the virus in vitro.
However, the specific changes responsible for attenuation via
this process are not understood, and empiric use of in vitro
adaptation to reduce vaccine virus virulence can produce
variable outcomes. Taking advantage of a newly developed rat
model for quantitative assessment of mumps virus neuroviru-
lence, here, we associate the genomic changes of in vitro
passaged viruses with neuroattenuation. Interestingly, despite a
dramatic decrease in virus virulence, the only genomic changes
were in form of changes in the level of genetic heterogeneity at
specific genome sites, i.e., either selection of one nucleotide
variant at positions where the starting material exhibited genetic
heterogeneity or the evolution of an additional nucleotide to
create a heterogenic site. It should be noted that the growth
kinetics of the virulent (Urabe P-AM9) and attenuated (Urabe
P6-CEF) viruses in brain were similar, suggesting that the
observed neuroattenuation is not due to an impaired ability of
the attenuated variant viruses to replicate. Nonetheless, the peak
titer of the neuroattenuated variant in rat brain was approxi-
mately one log lower than that of the more neurovirulent
parental strain. Whether or not this relatively small and transient
difference in viral load is biologically significant requires
further study. It is interesting to note that work with other
mumps virus strains showed that inoculation of rats with one
log less virus (10 pfu) or one log higher virus (1000 pfu) did not
significantly affect the severity of hydrocephalus, suggesting
that viral load per se is not responsible for disease severity
(unpublished data). Further, in a recent report, where neuro-virulent and neuroattenuated variants of a different mumps virus
strain (88–1961) were studied, differences in the extent of virus
infection, cell type tropism, spread or distribution in rat brain
were not observed (Rubin et al., 2003). This suggests that the
severity of hydrocephalus (as a measure of neurovirulence) is
more of a qualitative, rather than a quantitative, effect of the
virus on infected cells. For example, it is conceivable that
upon infection by Urabe P-AM9, ependymal cells (the major
target of mumps virus infection and the cell type responsible
for maintaining the homeostasis of cerebrospinal fluid flow
in the ventricular system) rapidly become functionally dis-
abled whereas Urabe P6-CEF infection of these cells may be
more sparing. This, and a number of other possibilities, includ-
ing lytic versus semi-persistent infection, requires further
study.
Determination of the complete nucleotide sequence of the
parental virus (Urabe P-AM9) and of the two neuroattenuated
variants (Urabe P6-CEF and Urabe P6-Vero) revealed limited
genomic changes at the nucleotide level. These changes
consisted solely of losses and gains in genomic heterogeneity
of the passaged viruses relative to the parental strain. In no case
did the new mutation in the passaged virus completely replace
the nucleotide seen in the parent virus.
In cases where the site-specific heterogeneity observed in the
parental virus was lost both in CEF and Vero cell passaged
viruses, there was a clear tendency towards selection of the
same nucleotide. While in most cases of heterogeneity loss, the
predominant nucleotide seen in the parental virus was selected
for, there were several instances of a strong selection for the
minority nucleotide. It is tempting to speculate that the tendency
to select for the same nucleotides in the neuroattenuated CEF
and Vero cell passaged viruses indicates a relevance of these
changes to the neuroattenuation phenotype.
In addition to loss of heterogeneous sites at some positions,
there was an apparent induction of heterogeneity at others. In
all such cases, one of the two nucleotides identified in these
heterogenic positions was present in the parental virus.
Intriguingly, we observed identical, but independent induction
of heterogeneity at position 5653 of the F-gene in Urabe P6-
Vero and Urabe P6-CEF, again suggesting a relevance of this
change to the neuroattenuation phenotype. Because our ability
to detect heterogeneous sites was limited to those sites with
differences of more than 10% between the detected nuc-
leotides in the consensus sequence, whether or not this
“induction” of heterogeneity is the result of the creation of de
novo mutations at these positions or is the selection of pre-
existing sequences within the minority quasispecies cannot be
ascertained.
As to which genes may influence the neuroattenuation
phenotype, these results suggest a combination of changes of
various genes may be important. Passaging of Urabe P-AM9
in CEF cells and Vero cells led to multiple predicted amino
acid changes in the NP, P, F, HN and L proteins. As the NP, P
and L proteins are involved in replication/transcription and
the HN and F proteins are involved in receptor recognition,
fusion events and nascent virus release from infected cells, it
is quite plausible that any or all predicted amino acid changes
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responsible for the observed attenuation. In addition, non-
coding changes occurred at one position in the untranslated 3′
leader region upon passage in CEF cells and at one intergenic
position upon passage in Vero cells. As untranslated regions
have a regulatory role in genome transcription and replication,Fig. 5. Schematic diagrams of the HN, F and L mumps virus proteins and the locati
are based on the crystal structure from Newcastle disease virus (NDV) (Crennell et al
numbers of β-strands and α-helices are indicated. The positions of identified aa het
conserved among all paramyxoviruses. (B) Identification of F protein domains was
Waxham et al., 1987), as well as based on sequence homologies to other paramyxo
cleavage site as well as of the resulting F1 and F2 subunits is indicated. Small numb
Urabe AM9, GenBank accession number AF314559). Large numbers indicate aa po
shown boxed. Letters in bold in the depicted sequence of the fusion peptide represen
protein domains were identified based on (Sidhu et al., 1993). Positions of the dom
conserved motif in domain IV is shown. Letters in bold define aa conserved am
conservative amino acid change.it is quite possible that changes in these regions may also
affect virus phenotype.
The precise role of these changes on virus function and
ultimately on virus virulence will require further study,
however, a few of the changes are worthy of discussion here.
As depicted in Fig. 5, all of the predicted amino acid changes inon of identified amino acid heterogeneities. (A) HN protein structural elements
., 2000). TM: transmembrane domain, LZ: leucine zipper domain. Location and
erogeneities are indicated below the diagram. Letters in bold depict aa that are
based on published protein data for mumps virus F protein (Liu et al., 2004;
viruses, in particular NDV (Chen et al., 2001). The position of the proteolytic
ers refer to amino acid positions of the various domains (based on mumps virus
sitions of heterogeneous sites (see also Table 1). The affected aa in the latter are
t aa highly conserved among paramyxoviruses (see Russell et al., 2004). (C) L
ains as well as of identified aa heterogeneities are indicated. The sequence of a
ong rubulaviruses. Panels A–C: nc: non-conservative amino acid change; c:
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which includes the receptor recognition and neuraminidase
active sites (Crennell et al., 2000; Zaitsev et al., 2004). Notably,
single point mutations in viral surface proteins, including ones
that lead to loss of N-linked glycosylation sites (as is predicted
for the Asn464Lys change), can affect virus virulence
(Guirakhoo et al., 2004; Hayasaka et al., 2004; Beasley et al.,
2005; Panda et al., 2004). The HN amino acid change at
position 335 is of particular interest as reports by others have
debated the role of a Lys to a Glu substitution at this position
with vaccine virulence (Brown and Wright, 1998; Brown et al.,
1996; Cusi et al., 1998; Mori et al., 1997; Afzal et al., 1998;
Amexis et al., 2001). In the present study, selection of Lys 335
was associated with attenuation.
As shown in Fig. 5, many of the predicted amino acid
changes in the F protein (responsible for fusion of the host cell
and viral membranes) and the L protein (part of the active RNA
dependent RNA polymerase) are located within highly
conserved motifs and domains (Morrison, 2003; Russell et al.,
2004; Horvath and Lamb, 1992; Poch et al., 1990; Sidhu et al.,
1993), suggesting a high potential for affect.
We also observed truncations of the genome ends, especially
of the 3′ ends, in some of the subcloned PCR fragments derived
from all three viruses. Such truncations may have potential
implications for efficient genome and antigenome replication,
which in the order mononegavirales is initiated at promoters at
the very ends of the genome that exhibit complementarity
(inverted terminal repeats). Truncations of genome ends has
recently been suggested to represent a strategy to control
replication (Schneider et al., 2005; Rosario et al., 2005).
Moreover, truncated genome ends have been described for
influenza virus (Szymkowiak et al., 2003) and members of the
Hantaan virus family, such as Seoul virus, possibly playing a role
in Hantaan virus persistence (Meyer and Schmaljohn, 2000).
However, since the majority of genome ends in our study were
complete and the observed deletions may also be due to RNA
degradation, presence of defective interfering particles or a
technical bias, the relevance of the observed terminal alterations
is unclear.
In summary, our data add further information to the
heterogeneous nature of the Urabe AM9 vaccine and demon-
strate that changes in viral genetic heterogeneity may have
dramatic impact on its neurovirulent potential in vivo. In
particular, our data suggest that proportions of viral quasispe-
cies, dynamic mixtures of viral particles whose genomic
sequences are closely related but differ at one or more
nucleotides (Holland et al., 1992; Domingo et al., 1996), may
play as significant a role in virulence as de novo genetic
mutations. The importance of genetic heterogeneity for viral
neuropathogenesis has been highlighted in a recent publication,
which demonstrated that cooperation/interdependence between
different virus variants, rather then selection of individual
viruses, is a determinant of pathogenesis. Accordingly, viral
populations rather than individual variants are proposed to be
target of evolutionary selection (Vignuzzi et al., 2005). Our data
suggest a partial or complete loss of heterogeneity during
passaging of Urabe AM9 in cell culture. It is thereforeconceivable that the interplay between different variants present
in the original virus seed, rather than one specific variant, is
critical for neurovirulence.
Taken together, examining the relative proportions of
heterogeneous sites of the whole genome, rather than solely
relying on a consensus sequence is an important consideration
in the study of the molecular basis of virus virulence.
Materials and methods
Cell lines
Vero (monkey kidney) and CEF (chicken embryo fibroblast)
cells were employed for serial passaging the parental Urabe P-
AM9 virus to obtain virus variants. Vero cells were cultivated in
Eagle's minimum essential medium (E-MEM, Quality Biolog-
ical, Gaithersburg, MD) supplemented with 2 mM L-glutamine
and 9% fetal bovine serum (FBS, Quality Biological, Gaithers-
burg, MD). The CEF cells were cultivated in Dulbecco's
modified Eagle's medium (Quality Biological, Gaithersburg,
MD) supplemented with 4.5 g/l glucose, 2 mM L-glutamine,
and 9% FBS.
Virus stock
The Urabe-AM9 vaccine strain (Pariorix), manufactured by
SmithKline Beecham Biologicals, was kindly provided by Drs.
Earl Brown and Kathryn Wright, University of Ottawa, Ontario,
Canada. Vaccine stock was expanded by passage twice in Vero
cells and stored at −70 °C. The resulting virus stock was
designated Urabe P-AM9.
Plaque assay for virus titer
Virus was serially diluted 10-fold in E-MEM, and 0.3 ml of
each dilution was incubated for 1 h at 37 °C on Vero cell
monolayers in 12-well plates. All virus dilutions were per-
formed in triplicate. Viral inoculum was removed by aspiration
and cells were immediately overlayed with 1 ml of warm (42 °C)
0.75% Difco agar noble (Becton, Dickinson and Company,
Sparks, MD) in 1× minimum essential medium (without phenol
red; Quality Biological) supplemented with 10% FBS. Follow-
ing incubation at 37 °C for 5 days, a second layer of 0.75%Difco
agar noble in 1× MEM containing 0.1% neutral red (Sigma-
Aldrich, St. Louis, MD), was subsequently added and incubated
overnight, allowing for visualization of the plaques the
following day. Virus was quantitated by counting the number
of plaque forming units (pfu) and multiplying by the reciprocal
of the dilution factor and volume plated.
Infection of cell lines and preparation of virus stocks
Confluent cell monolayers in 75 cm2 tissue culture flasks
were infected with Urabe P-AM9 at a multiplicity of infection
(m.o.i.) of 0.05 in a total volume of 5 ml cell culture medium.
Following incubation for 1 h at 37 °C, an additional 15 ml of
cell culture medium was added and cells were incubated for 7
55C.J. Sauder et al. / Virology 350 (2006) 48–57days (or earlier if cell lysis was evident). To harvest virus, cells
were mechanically detached from the flasks, and, along with
the supernatant, subjected to ultrasonic treatment and clarified
by centrifugation at 1200 rpm for 10 min. Harvested virus was
titered and used to infect additional cultures at an m.o.i. of
0.05. This procedure was repeated for a total of 6 passages.
For some passages a lower m.o.i. had to be used due to low
virus concentrations from the respective previous passages.
Virus stocks obtained after 6 passages in Vero and CEF cells
were designated Urabe P6-Vero and Urabe P6-CEF,
respectively.
Determination of virus titers in brains
Litters of 1-day-old Lewis rats (Harlan, Indianapolis, IN)
were inoculated intracerebrally with 20 μl of E-MEM contain-
ing 100 pfu of virus as previously described (Rubin et al., 1998).
On days 2, 3, 4, 5, 6, 8 and 10 p.i., the brains from 4 to 9 rats
from each virus group were removed aseptically. Brains were
homogenized into a 20% (wt/vol) suspension in E-MEM with
2% FBS by dounce homogenization, followed by three brief
pulses (10 s each) of ultrasonic treatment. Homogenates were
clarified by centrifugation at 2000 × g at 4 °C for 10 min and
stored at −70 °C until examination by plaque assay for virus
content per gram of brain.
Neurovirulence phenotype determination
The neurovirulence phenotype of the three virus strains
(Urabe P-AM9, Urabe P6-Vero and Urabe P6-CEF) was
assessed using the newborn rat-based method previously
described (Rubin et al., 2000, 2005). Briefly, on day 30 post-
inoculation (p.i.), rats were sacrificed by CO2 asphyxiation
following the NIH Guidelines for the Care and Use of
Laboratory Animals. Brains were removed, divided sagitally
and fixed in 10% neutral buffered formalin at 4 °C for 4–5 days,
followed by paraffin embedding. One 8–10 μm thick sagittal
section was selected at a standard distance from either side of
the anatomical midline and both were stained with hematoxylin
and eosin. The neurovirulence score, which is a measure of the
severity of mumps virus induced hydrocephalus, was deter-
mined by calculating the cross-sectional area of the brain
(excluding the cerebellum) and that of the lateral ventricle on
each tissue section using Image Pro Plus image analysis
software (Media Cybernetics, Silver Spring, MD). The mean
ratio (percentage) of these two measurements on each of the two
tissue sections per rat brain is the neurovirulence score for that
particular brain. The neurovirulence score for a given virus
variant is determined by the mean neurovirulence score for all
brains within a treatment group. At least three litters (consisting
of at least 7 animals each) were employed for a given virus
variant.
Preparation of mumps virus RNA
RNA from mumps virus stocks was extracted with a
QIAamp Minelute Virus Spin kit (Qiagen, Valencia, CA) asrecommended by the manufacturer. To extract total RNA from
mumps virus infected cells, cells were washed with PBS and
subsequently lysed with 1 ml of TRIZOL reagent (Invitrogen,
Carlsbad, CA). RNA then was prepared according to the
manufacturer's instructions.
Mumps virus genome sequencing
Viral RNA extracted from 50 to 75 μl of virus stock was
reverse transcribed using mumps virus specific primers.
Reverse transcription (RT) was done either using a superscript
II kit (Invitrogen) or a sensiscript RT kit (Qiagen) according to
the manufacturer's instructions. PCR was done using the
Expand high fidelity PCR system (Roche Diagnostics,
Indianapolis, IN). Overlapping fragments of 300 bp up to
2000 bp in length were amplified. Sequences of primers used
for RT-PCR can be obtained from the authors upon request.
PCR fragments were subjected to direct sequencing. To verify
presence of heterogeneous sites, selected PCR fragments were
additionally subcloned into plasmid pCR2.1-TOPO using the
TOPO TA cloning kit (Invitrogen). Four to 19 individual
subclones were prepared from each PCR product and were
sequenced. A summary of these results is shown in Table 1.DNA
sequencing was done using ABI PRISM BigDye terminator
sequencing chemistry (Applied Biosystems, Foster City, CA)
and ABI 377 or 3100 sequencing technology. Sequence
alignments were carried out using Jellyfish software (LabVelo-
city, Inc., Los Angeles, CA). To determine the 3′ ends of the
viruses, RNA extracted from 50 to 100 μl of virus stock was
subjected to tailing with A residues using poly-A polymerase
(USB, Cleveland, Ohio). After incubation for 15 min at 37 °C,
the RNAwas extracted with phenol/chloroform and precipitated
using ethanol/glycogen (Roche Diagnostics). A-tailed RNAwas
reverse transcribedwith a poly-Tadapter primer using a 3′RACE
system (Invitrogen). PCR was performed using 2.5 μl of cDNA,
10 pmol each of abridged universal amplification primer (3′
RACE kit, Invitrogen) and mumps virus specific primer NP437
(5′GAGCTTCAGGTGATCTATCTGC3′).
To determine the 5′ ends of Urabe P-AM9 and Urabe P6-
CEF, total RNAwas prepared from Vero cells or CEF cells 2 or
4 days after infection with Urabe P-AM9 or P6-CEF,
respectively. 5 μg of RNA each were subjected to RT with
Superscript II (5′ RACE system, Invitrogen) using 2.5 pmol of
mumps virus specific primer 14.75 (5′GGGCCAATCATCA-
GATCATGACAC3′). Following RNase incubation, cDNA
was column purified and 50% of the cDNA was tailed with C
residues using terminal deoxynucleotidyl transferase (5′
RACE system, Invitrogen) as recommended by the manufac-
turer. First round PCR (35 cycles) was performed using
2.5 μl of tailed cDNA, 2.5 units of Taq DNA polymerase
(Promega, Madison, WI), 20 pmol each of abridged anchor
primer (5′ RACE kit) and of mumps virus specific primer
14.75. Nested PCR (35 cycles) was performed with 1 μl of
first round PCR samples using 2.5 units of Taq DNA
polymerase (Promega) and 10–15 pmol each of abridged
universal amplification primer and mumps virus specific
primer 15105 (5′AAGCCATTGGGTGTGTAATC3′).
56 C.J. Sauder et al. / Virology 350 (2006) 48–57Due to technical issues, the 5′ end sequence of Urabe P6-
Vero was determined by self ligation. Briefly, RNA prepared
from 50 μl of virus stock was self-ligated using T4 RNA
ligase (NEB, Beverly, MA). After 1-h incubation at 37 °C,
RNA was extracted with phenol/chloroform and precipitated
using ethanol/glycogen. RNA was subjected to RT using the
ThermoScript RT System (Invitrogen). Incubation was done
for 1 h at 65 °C using mumps virus specific primer 15105.
First round PCR (36 cycles) was carried out using 2.5 μl of
primers 15105 and mu0rev (5′AATAACGAAGACTTT-
GACTGCTGAC3′). Nested PCR (35 cycles) using 1 μl of
first round product was done using primers 15272 (5′
CCAGCATCCAAATTCTTCTAGACC3′) and 117r (5′TCGA-
CAATGAAAGGTGAGGATCG3′). 5′- and 3′ RACE, as well
as RNA- ligation PCR products were both directly sequenced
and subcloned into pCR2.1-TOPO and four to eight subclones
each sequenced.
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